- Home
- ANEB vs ALVR Comparison
ANEB vs ALVR Comparison
Compare ANEB & ALVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANEB
- ALVR
- Stock Information
- Founded
- ANEB 2020
- ALVR 2013
- Country
- ANEB United States
- ALVR United States
- Employees
- ANEB N/A
- ALVR N/A
- Industry
- ANEB Biotechnology: Pharmaceutical Preparations
- ALVR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ANEB Health Care
- ALVR Health Care
- Exchange
- ANEB Nasdaq
- ALVR Nasdaq
- Market Cap
- ANEB 79.9M
- ALVR 87.7M
- IPO Year
- ANEB 2021
- ALVR 2020
- Fundamental
- Price
- ANEB $1.93
- ALVR $0.78
- Analyst Decision
- ANEB Buy
- ALVR Sell
- Analyst Count
- ANEB 1
- ALVR 5
- Target Price
- ANEB $8.00
- ALVR $1.00
- AVG Volume (30 Days)
- ANEB 13.3K
- ALVR 134.3K
- Earning Date
- ANEB 11-12-2024
- ALVR 10-31-2024
- Dividend Yield
- ANEB N/A
- ALVR N/A
- EPS Growth
- ANEB N/A
- ALVR N/A
- EPS
- ANEB N/A
- ALVR N/A
- Revenue
- ANEB N/A
- ALVR N/A
- Revenue This Year
- ANEB N/A
- ALVR N/A
- Revenue Next Year
- ANEB N/A
- ALVR N/A
- P/E Ratio
- ANEB N/A
- ALVR N/A
- Revenue Growth
- ANEB N/A
- ALVR N/A
- 52 Week Low
- ANEB $1.72
- ALVR $0.58
- 52 Week High
- ANEB $3.30
- ALVR $2.49
- Technical
- Relative Strength Index (RSI)
- ANEB 49.10
- ALVR 46.47
- Support Level
- ANEB $1.83
- ALVR $0.75
- Resistance Level
- ANEB $1.96
- ALVR $0.79
- Average True Range (ATR)
- ANEB 0.08
- ALVR 0.05
- MACD
- ANEB 0.00
- ALVR -0.01
- Stochastic Oscillator
- ANEB 49.09
- ALVR 32.00
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
About ALVR AlloVir Inc.
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.